Hepatitis Treatment News
A Smart + Strong Site
Subscribe to:
Hep Magazine In Bulk
Hep Newsletter
Join Us:

Back to home » Hepatitis Treatment News

November 24, 2015
More Good Hep C Cure Rates for Sovaldi/Velpatasvir
Sovaldi and velpatasvir, with or without ribavirin, yielded good results among people with various genotypes of hep C and decompensated cirrhosis.
Good Results for Sovaldi and Ravidasvir Treating Hep C Genotype 4
Twelve or 16 weeks of Sovaldi (sofosbuvir) and ravidasvir cured high rates of people with genotype 4 of hepatitis C virus in a recent large trial.
November 23, 2015
No Drop in Hep C Rates Among European Gays With HIV
Hepatitis C acquisition among HIV-positive European gay and bi men has steadily increased during the past 25 years, although trends vary by region, with evidence of a recent leveling-off effect in Western Europe.
8 Weeks of Harvoni + Vedroprevir Cures 96% of Hard-to-Treat Hep C
8 weeks of Harvoni (ledipasvir/sofosbuvir) and vedroprevir boasted a near-perfect cure rate among those with genotype 1 and advanced liver disease.
People With Hep B Have Raised Risk of Only Liver Cancer
Hepatitis B raises the risk of liver cancer, but not non-Hodgkin lymphoma, pancreatic cancer or cancer in general.
Gilead’s Sovaldi/Velpatasvir Cures High Rates of All Hep C Genotypes
Gilead Sciences’ Sovaldi (sofosbuvir) and velpatasvir posted near-perfect results in curing an array of genotypes of hepatitis C.
November 20, 2015
Hepatitis C Cure Often Leads to Improvement in Liver Health
Those with advanced fibrosis or cirrhosis who are cured of hepatitis C often experience regression of liver damage, improving by at least one fibrosis score.
Daklinza & Sovaldi Better Treats Those With HIV & HCV
Daklinza (daclatasvir) and Sovaldi (sofosbuvir) more effectively cures hepatitis C among those coinfected with HIV than does Sovaldi and ribavirin.
November 19, 2015
High Genotype 2 and 3 Hep C Cure Rates for New AbbVie Combo
AbbVie’s investigational hepatitis C treatments ABT-493 and ABT-530 posted mostly high cure rates among people with genotypes 2 and 3 of the virus.
Near-Perfect Results for New AbbVie Hep C Combo in Genotype 1s
Eight or 12 weeks of AbbVie’s investigational hepatitis C treatments ABT-493 and ABT-530 cured 97 to 100 percent of people with genotype 1.
November 18, 2015
Excellent Real-World Results for 8 Weeks of Hep C Treatment Harvoni
An eight-week treatment of Gilead Sciences’ hepatitis C treatment Harvoni has demonstrated excellent results in a real-world trial.
Promising Results for REP 2139 Treating Hep B and D Coinfection
A nucleic acid-based polymer called REP 2139, given alone and with interferon, has shown promise treating coinfection with hepatitis B and hepatitis delta.
Today’s Hep C Drugs May Avert Many Liver Transplants
The high success rate of today’s hepatitis C virus (HCV) treatments may keep many people from ultimately needing a liver transplant, freeing up available livers for others who require them.
November 17, 2015
Elbasvir/Grazoprevir Hep C Regimen Succeeds in Opiate Addicts
Elbasvir/grazoprevir cured high rates of individuals with genotypes 1, 4 or 6 of hepatitis C who inject drugs and are receiving opioid agonist therapy.
Hepatitis C May Transmit Sexually From Rectum Without Blood
Men may acquire hepatitis C virus sexually from the rectums of HIV/HCV-coinfected men even when there is no blood present.
November 16, 2015
Hep C Ups Risk of Anemia-Related Problems for Those on Dialysis
People on dialysis have a higher risk of anemia-related health complications if they have hepatitis C.
Daklinza and Sovaldi Cure High Rates of Hard-to-Treat Hep C
Daklinza (daclatasvir) and Sovaldi (sofosbuvir) plus ribavirin cured high rates of people with genotype 3 of hepatitis C and advanced fibrosis or cirrhosis.
Fast Responders May Only Need 3 Weeks of Triple Hep C Therapy
Individuals who experience a rapid undetectable viral load on a triple regimen of hepatitis C drugs may only need three weeks of treatment.
High Hep C Cure Rates for 8-Week Merck Triple Therapy
Merck’s grazoprevir, MK-3682, and either elbasvir or MK-8408, given for eight weeks, cured high rates of people with genotypes 1, 2 and 3 of hepatitis C in a recent trial.
High Hep C Cure Rates for Viekira Pak in Ongoing Liver Safety Study
AbbVie’s Viekira Pak cured 95 percent of people with genotype 1 of hepatitis C in an ongoing study of the long-term post-cure progression of liver disease.
Hep C Drug Resistance is Prevalent Among Screened VA Patients
People with hepatitis C whose physicians at the VA ordered drug  resistance tests show that more than half have a virus with resistance mutations.
November 13, 2015
FDA OKs Harvoni for Hep C Genotypes 4, 5, 6, People With HIV
The FDA has approved new indications for Gilead’s Harvoni: to treat hepatitis C in those with genotypes 4–6 of the virus and in those coinfected with HIV.
Medicaid Disproportionately Denies Hepatitis C Therapy Coverage
People seeking insurance coverage of hepatitis C treatment are much more likely to be denied if they have Medicaid rather than Medicare or private insurance.
November 11, 2015
Poor Results for New Syringe Designed to Curb Hep C Spread
A new type of syringe apparently falls short at lowering the risk of hepatitis C virus transmission.
November 09, 2015
Sovaldi and Harvoni May Cause Slow Heart Rate in Rare Cases
Hepatitis C regimens containing Gilead Sciences’ Sovaldi (sofosbuvir), including Harvoni (ledipasvir/sofosbuvir), may cause an abnormally slow heart rate in rare cases.
November 02, 2015
Curing Hep C Lowers Risk of Death in Those Coinfected With HIV
People coinfected with HIV and hepatitis C have a much lower risk of death after being cured of hep C.
Statins Slow Liver Disease in People With HIV and HCV
Non-cirrhotic people coinfected with HIV and hepatitis C are much less likely to experience liver disease progression if they are taking a statin.

November 2015
October 2015
September 2015
August 2015
July 2015
June 2015
May 2015
April 2015
March 2015
February 2015
January 2015
December 2014
November 2014
October 2014
September 2014
August 2014
July 2014
June 2014
May 2014
April 2014
March 2014
February 2014
January 2014
December 2013
November 2013
October 2013
September 2013
August 2013
July 2013
June 2013
May 2013
April 2013
March 2013
February 2013
January 2013
December 2012
November 2012
October 2012
September 2012
August 2012
July 2012
June 2012
May 2012
April 2012
March 2012
February 2012
January 2012
December 2011
November 2011
October 2011
September 2011
August 2011
July 2011
June 2011
May 2011
April 2011
March 2011
February 2011
January 2011
December 2010
November 2010
September 2010
August 2010
July 2010
June 2010
May 2010
April 2010
March 2010
February 2010
January 2010
December 2009
November 2009
October 2009
September 2009
August 2009
July 2009
June 2009
May 2009
April 2009
March 2009
February 2009
January 2009
December 2008
October 2008
September 2008
August 2008
July 2008
June 2008
May 2008
April 2008
March 2008
January 2008


Current Issue
Hep Stories
Services Directory
Conference News
Top Stories
Treatment News
Hep Exclusives
All About Hepatitis
• Hepatitis A
• Hepatitis B
• Hepatitis C
HCV/HIV Coinfection
Help Paying For Meds
Clinical Trials
Tell us what you think
Do you experience fatigue regularly?

Hepatitis C Reader Survey
© 2015 Smart + Strong. All Rights Reserved. Terms of use and Your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.